CAVA heads into its June 22 earnings with a fresh analyst upgrade on one side and a quietly persistent short base on the other.
The most immediate catalyst this week came from the Street. UBS upgraded CAVA to Buy from Neutral on Tuesday, lifting its target from $85 to $90 — a meaningful endorsement given the stock's recent pullback from its highs. The move aligns with a broader post-earnings consensus shift: following the Q1 print in late May, RBC raised its target to $105, Piper Sandler moved to $92, and Telsey lifted to $95. All maintained positive ratings. The sole holdout in tone is Barclays, which kept Equal-Weight and nudged its target to only $74 — the most skeptical read on the Street. With the consensus at Buy and a mean target of $92 against a current price of $76.28, the implied upside is roughly 20%. That said, the bull case rests on same-store sales acceleration and digital engagement, while bears point to margin pressure from higher input costs and a new menu item — salmon — that is unlikely to move the needle on its own.
Short interest is elevated but not tightening. At 12.3% of the free float, the short base is meaningful, and it has edged roughly 5% higher over the past month. Yet the borrow market tells a less urgent story. Availability is running at around 316% — more than three shares available to lend for every two already borrowed — well above the 52-week low of 111%. That reading has actually loosened over the past week by roughly 23%, suggesting the pool of shares to borrow expanded even as short interest nudged higher. Cost to borrow has drifted down nearly 10% on the week to 0.43%, one of the lowest levels in the trailing 30-day window. The short score sits at 61.8, broadly stable across the past two weeks. Taken together, the positioning looks elevated in volume terms but not pressured in lending-market terms — there is no squeeze mechanics building here.
Options tell a more cautious story heading into the print. The put/call ratio has been running above its recent average all week, reaching 0.79 against a 20-day mean of 0.70 — roughly 1.5 standard deviations above normal, and near the top end of the past year's range. That shift has been consistent since early June, when the ratio climbed from the high-0.50s it held through most of May. Options traders are paying more for downside protection now than at any recent point outside the 0.91 annual high.
Insider activity adds an interesting counterpoint. The COO, Douglas Thompson, bought a combined 6,500 shares in late May across two separate purchases, putting roughly $510,000 to work between $77.90 and $79.45 per share. The company secretary also bought twice in the same window. On the other side, the HR director and Chief Accounting Officer sold in May — though those sales carried lower significance scores and are common around vesting schedules. Net insider activity over 90 days is modestly positive at just under 48,000 shares. The COO's cluster of purchases near current price levels is notable in isolation, particularly ahead of a catalyst.
The June 22 print is the next focal point: the question is whether same-store sales momentum from Q1 carries into Q2, and whether management can show any progress on the margin line that the bear case says remains structurally pressured.
See the live data behind this article on ORTEX.
Open CAVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
